Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth’s Hot Flash: Pristiq “Approvable” Delays Vasomotor Claim At Least A Year

Executive Summary

Building a stable of next-generation women's health products is not coming easily to Wyeth. The drug maker received an "approvable" letter July 23 for its Effexor XR follow-on Pristiq for treatment of vasomotor symptoms of menopause, including night sweats and hot flashes

Related Content

First Non-Hormonal Hot Flash Drugs Could Clear FDA Panel In March
Wyeth Looks To Specialty Markets As Generics Challenge Current Model
JPMorgan Healthcare Conference In Brief
Tablet & Teva Block Sun As Generic Competition For Wyeth’s Effexor XR
Pending NDAs To Be Poussot’s Top Priority As Wyeth’s Upcoming CEO
Poussot Tapped As Wyeth CEO – Inherits Full Pipeline, Takeover Concerns
Wyeth’s bifeprunox “not approvable”
Wyeth Seeks Silver Lining In Series Of Regulatory Setbacks
Wyeth Struggling To Avoid Depressed Market For Pristiq
Wyeth Struggling To Avoid Depressed Market For Pristiq



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts